vimarsana.com

Latest Breaking News On - David urso - Page 1 : vimarsana.com

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab

MEI Pharma (MEIP) Reports Initial Data from Study of ME-344 in Combination with Bevacizumab
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344

MEI Pharma (MEIP) Board Aligns on Strategy to Advance Voruciclib and ME-344
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344

– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital,.

MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum

MEI Pharma, Inc. , a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.